In brief

Wyeth reached an agreement with Seattle biotechnology company Trubion to back its development of drugs based on molecules known as small modular immunopharmaceuticals, or SMIPs. The New Jersey drug company will invest $40-million in Trubion immediately, with up to $800 million to follow if certain milestones are met.

To read this story in full you will need to login or make a payment (see right).

HTTP Status 500 -

---

type Exception report

message

description The server encountered an internal error () that prevented it from fulfilling this request.

exception

javax.servlet.ServletException: Servlet execution threw an exception

root cause

java.lang.OutOfMemoryError

note The full stack trace of the root cause is available in the Tomcat logs.

---

Apache Tomcat/5.0.7